Memantine +/- Raloxifene for Brain Tumor
(MemoryRT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether adding raloxifene (a medication typically used for osteoporosis) to memantine (a drug for memory loss) can delay memory problems in patients undergoing radiation treatment for brain cancer. Participants will be divided into two groups: one will receive standard memantine treatment, while the other will receive both memantine and raloxifene. The study seeks adults about to start radiation therapy for a brain tumor. Candidates should not have had previous brain radiation and must be able to undergo an MRI.
As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to significant advancements in brain cancer care.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Previous studies have shown that memantine is safe for patients. It is already used to treat conditions like Alzheimer’s disease, demonstrating a strong safety record. Most reported side effects are mild, such as dizziness or headache.
Raloxifene has also undergone study for its effects on the brain. Research shows it may help protect against brain damage and could reduce the risk of mild memory problems by 33% in postmenopausal women. However, it may increase the risk of stroke, so discussing concerns with a doctor is important.
Both treatments have been used in other contexts, providing researchers with a good understanding of their safety. Always discuss potential risks and benefits with a healthcare provider.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments because Memantine, typically used to manage symptoms of Alzheimer's, is being explored for its potential to protect brain cells during radiation therapy for brain tumors. This is intriguing because it could help reduce cognitive side effects often associated with radiation. Additionally, Raloxifene, commonly used in osteoporosis, is being examined for its ability to impact tumor growth by modulating estrogen receptors. The combination of these two drugs could offer a unique approach, potentially enhancing the effectiveness of standard care while minimizing negative side effects on brain function.
What evidence suggests that this trial's treatments could be effective for brain cancer?
Studies have shown that memantine can protect memory in patients receiving radiation for brain cancer by blocking certain overly active brain receptors. In this trial, participants in Group A will receive memantine as part of the standard care. Research also suggests that raloxifene, another drug tested in this trial, might protect brain cells by reducing harmful stress in the brain and possibly improving brain function. Participants in Group B will receive both memantine and raloxifene. Although more information is needed, these findings suggest that combining raloxifene with memantine might better protect memory during cancer treatment.14678
Are You a Good Fit for This Trial?
This trial is for adults (18+) with brain tumors who are about to receive radiation therapy. Participants must have good kidney and liver function, be able to consent, not be pregnant, and agree to use birth control if needed. People can't join if they have severe cognitive problems, prior brain radiation, or allergies to the study drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive radiation therapy to the brain, with memantine as standard of care, and raloxifene for Group B
Treatment
Participants continue memantine treatment, with Group B also receiving raloxifene
Follow-up
Participants are monitored for cognitive function and quality of life outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Memantine
- Raloxifene
Trial Overview
The study tests whether adding raloxifene to memantine helps protect memory in people getting brain radiation for cancer. Participants will get either memantine alone or both drugs during their treatment.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients will start Memantine as SOC around the time of radiation. Memantine may be continued as SOC as prescribed by the treating physician after the 24 weeks. If randomized to group B patients will be recommended to start the assigned Raloxifene at least one week before their anticipated RT treatment start date.
Patients will start Memantine as SOC around the time of radiation. Memantine may be continued as SOC as prescribed by the treating physician after the 24 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center at San Antonio
Lead Sponsor
Citations
Association of raloxifene and tamoxifen therapy with cognitive ...
Our results demonstrate that the use of these medications was not associated with global or domain‐specific cognition, odds of MCI, or structural MRI markers ...
Raloxifene prevents stress granule dissolution, impairs ...
Raloxifene prevents stress granule dissolution, impairs translational control and promotes cell death during hypoxia in glioblastoma cells.
Raloxifene as Treatment for Various Types of Brain Injuries ...
Recent studies have shown that the selective estrogen receptor modulator (SERM) raloxifene had pronounced protective effects against progressing brain ...
(PDF) Association of raloxifene and tamoxifen therapy with ...
Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of ...
Raloxifene exposure enhances brain activation during ...
When compared to placebo, raloxifene treatment significantly enhanced activation in these structures (Z > 3.1), except for mediotemporal areas. Task performance ...
Raloxifene as Treatment for Various Types of Brain Injuries ...
Recent studies have shown that the selective estrogen receptor modulator (SERM) raloxifene had pronounced protective effects against progressing brain damage ...
Neuroprotective Potential of Raloxifene via G-Protein- ...
Our findings suggest that raloxifene safeguards against Aβo-induced neurotoxicity by modifying oxidative parameters and maintaining [Ca2+]i homeostasis.
Effect of Raloxifene on Prevention of Dementia and ...
Raloxifene, at a dose of 120 mg/day, reduced the risk of developing mild cognitive impairment by 33% among postmenopausal women with ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.